Form 4: Arcutis Biotherapeutics Director Sells Shares
Insider Transaction (Form 4)
Terrie Curran, a Director of Arcutis Biotherapeutics, Inc., sold 38,200 shares of common stock on August 27, 2026 for $25.03 per share.
Summary
- Option exercise/conversion: acquired 11,148 Common Stock at $7.51 ($83,721) on August 27, 2026; holds 34,674 after (Direct).
- Open-market sale: disposed of 11,148 Common Stock at $25.03 ($279,028) on August 27, 2026; holds 23,526 after (Direct).
- Option exercise/conversion: acquired 27,052 Common Stock at $8.63 ($233,459) on August 27, 2026; holds 50,578 after (Direct).
- Open-market sale: disposed of 27,052 Common Stock at $25.03 ($677,095) on August 27, 2026; holds 23,526 after (Direct).
- Option exercise/conversion: disposed of 11,148 Stock Option (right to buy) on August 27, 2026 (Direct).
- Option exercise/conversion: disposed of 27,052 Stock Option (right to buy) on August 27, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $956,123 of stock on the open market.
Insider Transactions
Terrie Curran — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-27 | Option exercise/conversion | Common Stock | 11,148 | $8 | $83.7K | 34,674 |
| 2026-08-27 | Open-market sale | Common Stock | 11,148 | $25 | $279.0K | 23,526 |
| 2026-08-27 | Option exercise/conversion | Common Stock | 27,052 | $9 | $233.5K | 50,578 |
| 2026-08-27 | Open-market sale | Common Stock | 27,052 | $25 | $677.1K | 23,526 |
| 2026-08-27 | Option exercise/conversion | Stock Option (right to buy) | 11,148 | — | — | 0 |
| 2026-08-27 | Option exercise/conversion | Stock Option (right to buy) | 27,052 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-27 | Option exercise/conversion (11,148 shares) |
| 2026-08-27 | Open-market sale (11,148 shares) |
| 2026-08-27 | Option exercise/conversion (27,052 shares) |
| 2026-08-27 | Open-market sale (27,052 shares) |
| 2026-08-27 | Option exercise/conversion (11,148 shares) |
| 2026-08-27 | Option exercise/conversion (27,052 shares) |
Keywords
insider transaction, Form 4, ARQT, Arcutis Biotherapeutics, Inc., bearish, Terrie Curran
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.